Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A clinically and genetically heterogeneous group of neurodegenerative diseases characterized by a slowly progressive ataxia of gait, stance and limbs, dysarthria and/or oculomotor disorder, due to cerebellar degeneration in the absence of coexisting diseases. The degenerative process can be limited to the cerebellum (ADCA type 3) or may additionally involve the retina (ADCA type 2), optic nerve, ponto-medullary systems, basal ganglia, cerebral cortex, spinal tracts or peripheral nerves (ADCA type 1). In ACDA type 4, a cerebellar syndrome is associated with epilepsy.
No HPO annotations are available for this condition.
Age of onset: later in life, middle age.
Spinocerebellar ataxia type 7 (SCA7) comprises a phenotypic spectrum ranging from adolescent- or adult-onset progressive cerebellar ataxia and cone-rod retinal dystrophy with progressive central visual loss to infantile or early-childhood onset with multiorgan failure, an accelerated course, and early death . One important aspect of SCA7 clinical manifestations is their extreme variability with respect to age of onset and rate of progression. Affected individuals may present in infancy, childhood, adolescence, young adulthood, middle age, or old age. When onset is at or before adolescence, initial manifestations are typically impaired vision, ultimately progressing to blindness from retinal degeneration. Individuals with manifestations in their teens may be blind within a decade or less. In adults, the progressive cerebellar ataxia (i.e., dysmetria, dysdiadochokinesia, and poor coordination) usually precedes the onset of visual manifestations. The age of onset inversely correlates with rate of progression and extent of symptomatology, as onset in or after the fifth decade of life gives a predominant cerebellar ataxia without progression to significant visual impairment, whereas onset prior to middle age often features progression to vision loss. Progression to severe disability resulting in death varies based on age of onset, ranging from months in infants to fewer than ten years in older children to two to three decades in adolescents and adults. While the rate of progression varies, the eventual result for almost all affected individuals is severe dysarthria, dysphagia, and a bedridden state with loss of motor control. To date, more than 1,000 individuals with SCA7 have been identified worldwide. Frequency of select features in adolescent- or adult-onset disease are summarized in . Adolescent- or Adult-Onset SCA7 Table 2. Select Features of Adolescent- or Adult-Onset SCA7
Spinocerebellar ataxia type 7 (SCA7) should be suspected in individuals with the following (by age) and .
Clinical Findings
Adult onset
Progressive incoordination caused by cerebellar ataxia, including dysarthria/dysphagia, dysmetria, and dysdiadochokinesia.
Cone-rod retinal dystrophy with the following:
No approved treatments are currently available for autosomal dominant cerebellar ataxia. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 7 (SCA7) of adolescent or adult onset, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Table 6.
Recommended Surveillance for Individuals with SCA7
System/Concern | Evaluation | Frequency
|
Neurologic assessment for progression of ataxia; UMN or LMN signs; dystonia parkinsonism; autonomic dysfunction
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
188 publications have been identified in PubMed for autosomal dominant cerebellar ataxia. Research spans Basic Science / Preclinical (34%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 63 | 34% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:25 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Cerebellar ataxia | 100% | Unsteady gait; finger-to-nose dysmetria |
Dysarthria | 100% | Garbled or slurred speech |
Dysphagia | 40% | Difficulty swallowing Oculomotor |
abnormalities | 80% | Slowed ocular saccades; Ophthalmoplegia Motor neuron |
degeneration | 100% | Upper motor neuron involvement (hyperreflexia, spasticity); may resemble hereditary spastic paraplegia.; Lower motor neuron involvement (fasciculations, weakness w/muscle wasting, areflexia, distal sensory loss) |
Sensory loss | 40% | sensation to light touch, pinprick, /or joint position Restless leg |
syndrome | 35% | Discomfort in legs resulting in uncontrollable urge to move ones legs, typically worse in evening or nighttime |
Cognitive decline | 20% | Impaired executive function Behavior disorder/ |
Psychosis | 10% | Altered mentation; Impaired reality testing Cone-rod |
dystrophy | 70% | Loss of central vision color vision Neurologic findings. In adult-onset disease (age 30 years), cerebellar ataxia (manifesting as difficulty with walking, manual dexterity, and speech) is the most common clinical feature and is often the first reported manifestation . |
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
Loss of central vision
A tritan-axis (blue/yellow) defect on detailed color vision testing
Macular changes on fundoscopic examination
Paracentral scotoma on visual field testing
On electroretinogram (ERG), abnormalities of cone function initially, followed by abnormalities of rod function
Infantile or early-childhood onset
Failure to thrive and loss of motor milestones (may be the earliest findings)
Rapid deterioration with early death
Ataxia and visual loss not obvious
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
While many of the neurologic and pathologic findings of the other spinocerebellar ataxias (SCAs) overlap with SCA7, retinal degeneration is the distinguishing feature of SCA7 (see Hereditary Ataxia Overview). Table 3. Disorders with Retinal Degeneration in the Differential Diagnosis of Spinocerebellar Ataxia Type 7
Gene(s) | Disorder | MOI | Eye Findings | Neurologic Pathologic Findings | Distinguishing Features |
|---|---|---|---|---|---|
CRX | Cone-rod dystrophy 2 (OMIM 120970) | AD | Impaired color vision; central scotoma | No neurologic findings | No neurologic findings MT-ND1MT-ND4MT-ND61 |
Leber hereditary optic neuropathy | Mat | Impaired color vision; central scotoma | No neurologic findings | Usually midlife presentation | — |
OPA3 | Costeff syndrome (3-methylglutaconic aciduria type 3) | AR | Bilateral optic atrophy | Chorea, spastic paraparesis, mild ataxia | Optic atrophy in childhood (age 10 yrs); Common in persons of Iraqi Jewish origin due to founder variant WFS1 |
CISD2 | Wolfram syndrome(See WFS1 Wolfram Syndrome Spectrum Disorder.) | AR | Bilateral optic trophy | Ataxia, diabetes mellitus/insipidus, hearing loss | Childhood-onset diabetes mellitus optic atrophy AD = autosomal dominant; AR = autosomal recessive; Mat = maternal; MOI = mode of inheritance Three common mtDNA pathogenic variants in the listed genes account for 90%-95% of Leber hereditary optic neuropathy (LHON). |
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
Biomarker and diagnostic research for autosomal dominant cerebellar ataxia has been reported in the published literature.
System/Concern | Evaluation | Comment
| Neurologist assessment for cerebellar motor dysfunction (gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades smooth pursuit) | Use standardized scale to establish baseline for ataxia (SARA, ICARS, or BARS).1
UMN /or LMN dysfunction (weakness, spasticity, Babinski signs, hyperreflexia, amyotrophy, fasciculations) | Since most exhibit some corticospinal tract involvement, comprehensive assessment of motor sensory function recommended for all affected persons
Refer to neuromuscular clinic (OT/PT / rehab specialist). | Assess gross motor fine motor skills, gait, ambulation, need for adaptive devices, PT, OT.
Ophthalmologic
involvement | Complete eye exam | Incl:
BCVA
Extraocular movement
Refractive error
Color vision testing
Full-field ERG
Spectral-domain OCT
| For those w/dysarthria: speech/language eval | Consider involving certified practitioner of speech/language pathology.
| For those w/frequent choking or severe dysphagia, assess:
Nutritional status;
Aspiration risk.
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
Avoid drinking alcoholic beverages, as alcohol intake can further impair cerebellar function, especially if excessive. Avoid foods identified by a registered dietician as potentially causing dizziness or disorientation.
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
Ongoing clinical trials for SCA7 include a study of:
Troriluzole in adults as a treatment for ataxia in the United States (ClinicalTrials.gov: NCT03701399);
Riluzole in adults as a treatment for ataxia in Italy (ClinicalTrials.gov: NCT03660917).
Ionis Pharmaceuticals is developing an antisense oligonucleotide for dosage reduction of ataxin-7 in the retina and brain, as a preclinical trial of this strategy was found to be an effective treatment for retinal degeneration in an SCA7 mouse model . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
1 trial found
Monitor ataxia progression w/standardized scale (SARA, ICARS, or BARS).1
| Annually; more often for an acute exacerbation
Physiatry; OT/PT assessment of mobility; self-help skills as they relate to ataxia, spasticity, weakness
| Assess need for alternative communication method or speech therapy. | Per symptom progression
| Assess aspiration risk feeding methods.
| Exam by ophthalmologist for evidence of cone-rod dystrophy: BCVA, color vision testing, visual field testing, ERG | Every 3-5 yrs or as needed based on concerns re visual acuity, visual field deficits, /or color vision (as an indicator of cone function)
Cognitive/
| Evaluate mood, signs of psychosis, cognitive complaints to identify need for pharmacologic psychotherapeutic interventions. | Per symptom progression development of psychiatric symptoms
Family support/
resources | Provide various options for affected persons their families, ranging from joining patient support groups (e.g., National Ataxia Foundation, which has local chapters throughout the US) to social work consultation. | Per symptom progression
Source: GeneReviews — "Spinocerebellar Ataxia Type 7"
Estimated prevalence: 1-9 in 100,000 (Uncommon).
Disease patterns and progression |
37 |
20% |
Research summaries | 34 | 18% |
Patient case studies | 17 | 9% |
Testing and diagnosis research | 15 | 8% |
Clinical study results | 10 | 5% |
New treatment approaches | 9 | 5% |
Other research | 3 | 2% |
Vinokurov E (2026). [PMID: 42057699](https://pubmed.ncbi.nlm.nih.gov/42057699/). *Neurodegener Dis Manag*. [Review / Meta-Analysis]
Yellaturi SR (2026). [PMID: 42220968](https://pubmed.ncbi.nlm.nih.gov/42220968/). *Tremor Other Hyperkinet Mov (N Y)*. [Review / Meta-Analysis]
Ransdell JL (2026). [PMID: 41558966](https://pubmed.ncbi.nlm.nih.gov/41558966/). *The Journal of neuroscience : the official journal of the Society for Neuroscience*. [Epidemiology / Natural History]
Melzer I (2026). [PMID: 42115447](https://pubmed.ncbi.nlm.nih.gov/42115447/). *Cerebellum*. [Review / Meta-Analysis]
Liu Y (2026). [PMID: 41530546](https://pubmed.ncbi.nlm.nih.gov/41530546/). *Journal of human genetics*. [Case Report / Case Series]
Pieper AA (2026). [PMID: 41398098](https://pubmed.ncbi.nlm.nih.gov/41398098/). *Handb Exp Pharmacol*. [Review / Meta-Analysis]
Kerkhof LMC (2026). [PMID: 41620186](https://pubmed.ncbi.nlm.nih.gov/41620186/). *Neurobiol Dis*. [Basic Science / Preclinical]
Bhandari J (2026). [PMID: 32491748](https://pubmed.ncbi.nlm.nih.gov/32491748/). *Unknown Journal*. [Review / Meta-Analysis]
Mancini M (2026). [PMID: 41456196](https://pubmed.ncbi.nlm.nih.gov/41456196/). *Neurorehabil Neural Repair*. [Basic Science / Preclinical]
Nordick K (2026). [PMID: 31424834](https://pubmed.ncbi.nlm.nih.gov/31424834/). *Unknown Journal*. [Review / Meta-Analysis]